Harmony Biosciences Announces Plans to Initiate Phase 3 Registrational Study of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences, a pharmaceutical company focused on developing therapies for rare neurological diseases, has announced its plans to conduct a Phase 3 registrational study of pitolisant in individuals with Prader-Willi syndrome (PWS) who are experiencing excessive daytime sleepiness (EDS). This study will include children, adolescents, and adults with PWS. The decision to proceed with the st..